Maxim Group's healthcare analyst Jason Kolbert came out with a negative view on Neuralstem, Inc. (NYSE MKT:CUR), after the company reported its fourth-quarter results and provided …
Maxim Group's healthcare analyst Jason Kolbert came out with a research note on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the company reported its fourth-quarter financial results and provided a corporate …
Maxim’s healthcare analyst Jason Kolbert came out today with a research note on Synthetic Biologics Inc (NYSE MKT:SYN), downgrading shares from Buy to Hold, and reiterating $3 …
In a research report issued this morning, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Omeros Corporation (NASDAQ:OMER) and slightly raised the price …
In a research report released this morning, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Cytori Therapeutics Inc (NASDAQ:CYTX) with a price target …
Maxim Group analyst Jason Kolbert came out today with an update on IsoRay, Inc. (NYSE MKT:ISR), after the company released it’s fiscal second-quarter results this morning.
Maxim Group analyst Jason Kolbert came out with an update on Brainstorm Cell Therapeutics (NASDAQ:BCLI), as the company announced that it received a Notice of Allowance from …
Maxim’s healthcare analyst Jason Kolbert weighed in with his thoughts on Galena Biopharma (NASDAQ:GALE), after the company announced enrollment of the 700th patient in the …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, as …
In a research report published Monday, Maxim analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with an $8.00 price target, …
